London
· Delayed Price · Currency is GBP · Price in SEK Hansa Biopharma AB Statistics
Total Valuation
LON:0RC7 has a market cap or net worth of GBP 131.20 million. The enterprise value is 190.58 million.
| Market Cap | 131.20M |
| Enterprise Value | 190.58M |
Important Dates
The last earnings date was Thursday, April 24, 2025.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 67.81M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +26.66% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 37.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.37 |
| PB Ratio | -2.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.95 |
| EV / Sales | 13.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.87 |
Financial Position
The company has a current ratio of 1.83
| Current Ratio | 1.83 |
| Quick Ratio | 1.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.60 |
| Interest Coverage | -5.70 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -46.04% |
| Return on Invested Capital (ROIC) | -73.10% |
| Return on Capital Employed (ROCE) | -126.92% |
| Revenue Per Employee | 101,516 |
| Profits Per Employee | -349,631 |
| Employee Count | 135 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 42.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.74% in the last 52 weeks. The beta is 1.65, so LON:0RC7's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -27.74% |
| 50-Day Moving Average | 23.59 |
| 200-Day Moving Average | 33.21 |
| Relative Strength Index (RSI) | 50.91 |
| Average Volume (20 Days) | 5,150 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LON:0RC7 had revenue of GBP 14.01 million and -48.25 million in losses. Loss per share was -0.72.
| Revenue | 14.01M |
| Gross Profit | 7.38M |
| Operating Income | -43.62M |
| Pretax Income | -47.99M |
| Net Income | -48.25M |
| EBITDA | -43.43M |
| EBIT | -43.62M |
| Loss Per Share | -0.72 |
Balance Sheet
The company has 19.29 million in cash and 78.51 million in debt, giving a net cash position of -59.21 million.
| Cash & Cash Equivalents | 19.29M |
| Total Debt | 78.51M |
| Net Cash | -59.21M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -48.10M |
| Book Value Per Share | -0.71 |
| Working Capital | 16.65M |
Cash Flow
In the last 12 months, operating cash flow was -49.16 million and capital expenditures -48,423, giving a free cash flow of -49.21 million.
| Operating Cash Flow | -49.16M |
| Capital Expenditures | -48,423 |
| Free Cash Flow | -49.21M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 52.71% |
| Operating Margin | -311.34% |
| Pretax Margin | -342.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0RC7 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.66% |
| Shareholder Yield | -26.66% |
| Earnings Yield | -36.78% |
| FCF Yield | -37.51% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |